Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors.
about
Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancerRecent Advances in Immunotherapy in Metastatic NSCLCElevated frequencies of CD8 T cells expressing PD-1, CTLA-4 and Tim-3 within tumour from perineural squamous cell carcinoma patients.Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor.TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action.The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System.Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics.Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacyInterleukin-2 reverses CD8(+) T cell exhaustion in clinical malignant pleural effusion of lung cancer.Quantification of hepatocellular carcinoma heterogeneity with multiparametric magnetic resonance imagingThe PD-L1/PD-1 pathway promotes dysfunction, but not "exhaustion", in tumor-responding T cells from pleural effusions in lung cancer patients.Epigenetic regulation of immune checkpoints: another target for cancer immunotherapy?T cell exhaustion: from pathophysiological basics to tumor immunotherapy.The immune contexture in cancer prognosis and treatment.Characterization of infiltrating lymphocytes in human benign and malignant prostate tissue.CTLA-4 expression in the non-small cell lung cancer patient tumor microenvironment: diverging prognostic impact in primary tumors and lymph node metastases.Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade.How to evaluate the immune status of lung cancer patients before immunotherapy.Immune checkpoint inhibitors in advanced non-small cell lung cancer.Comprehensive T-cell immunophenotyping and next-generation sequencing of human papillomavirus (HPV)-positive and HPV-negative head and neck squamous cell carcinomas.Pulmonary pleomorphic carcinoma with few PD-1-positive immune cells and regulatory T cells that showed a complete response to nivolumab.Mechanisms of resistance to immune checkpoint inhibitors.Immune checkpoint therapy in liver cancer.TIM-3, a promising target for cancer immunotherapyPresence of few PD-1-expressing tumor-infiltrating immune cells is a potential predictor of improved response to salvage chemotherapy following nivolumab for non-small cell lung cancer: An exploratory case series
P2860
Q26740288-206FE680-409D-49D0-9D2E-DAA8AA69AB41Q28069323-0944E6C9-C652-43EA-AF0D-C64D091CB875Q33579474-7EF7988B-C836-4DF9-BB49-0508895F403BQ36711034-D01FE210-D856-4085-902D-11915F405439Q37729313-887330C2-4322-4C10-902F-9EB05AD3F533Q38401891-3BC6AC63-F5AD-4642-B1A5-AEF759952680Q38646993-48D5C45A-261A-4754-A2C9-F3FE4D321E54Q38749824-0336A3CD-90E7-4AC5-A3A7-08C95EC40BD0Q38756417-FA0928D2-ED85-4A26-B487-15F9F9E69DBFQ38760629-18C2AD84-EA87-4C18-AE3E-CD4263DDDAEAQ38910078-9F9E08F9-169C-4C1B-A846-A6BE92CCA9D1Q39045550-B3436ADF-B3AE-45DB-9E87-FDB7C36AB748Q39078341-C2C5B902-0C54-4F45-8A22-0E2C900B913AQ39456999-D6B248B2-E4E8-4D6A-8BEA-6E0BFE78D0D6Q41694140-3D749471-3B48-4EAB-8193-10F789D48F45Q42683596-270DC3AC-F457-40FC-BFC7-D6109BCE6966Q47135020-A0C94D9C-A673-4285-8012-C9A2047287D5Q47167817-557875DE-B97C-4939-A806-A4689C047BA1Q47563451-545BE125-6356-487D-8E79-5D1DB6F27E79Q47683846-9420687E-A7F2-42AA-9F72-7289E5832315Q47713714-4860567D-7046-4B1B-BF76-D6DB8386EDCBQ49537326-B588197E-7A15-4AC1-B7D8-8210FD5098DBQ55008806-188D517C-471E-4EC3-999F-1ADC2B122644Q58558279-B4EB1220-79C3-4717-8BA7-A816BE8AE278Q58732728-AF436410-091C-4189-AD4A-746CE126603A
P2860
Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Progression of Lung Cancer Is ...... Multiple Inhibitory Receptors.
@ast
Progression of Lung Cancer Is ...... Multiple Inhibitory Receptors.
@en
type
label
Progression of Lung Cancer Is ...... Multiple Inhibitory Receptors.
@ast
Progression of Lung Cancer Is ...... Multiple Inhibitory Receptors.
@en
prefLabel
Progression of Lung Cancer Is ...... Multiple Inhibitory Receptors.
@ast
Progression of Lung Cancer Is ...... Multiple Inhibitory Receptors.
@en
P2093
P1476
Progression of Lung Cancer Is ...... Multiple Inhibitory Receptors.
@en
P2093
Alfred Zippelius
Andreas Roller
Anton Belousov
Christian Klein
Didier Lardinois
Jens Schreiner
Marina Bacac
Ozana S Fischer
Pablo Umana
Pavel Pisa
P304
P356
10.1158/2326-6066.CIR-15-0097
P577
2015-08-07T00:00:00Z